| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/21/2011 | US20110177099 Genetic variations associated with drug resistance |
| 07/21/2011 | US20110177095 Anti-her2 antibodies and their uses |
| 07/21/2011 | US20110177092 Individual 5-fluorouracile dose optimization in folfiri treatment |
| 07/21/2011 | US20110177091 Inhibition of Tumor Angiogenesis by Inhibition of Peroxiredoxin 1 (PRX1) |
| 07/21/2011 | US20110177088 Method for Treating and Diagnosing Hematologic Malignancies |
| 07/21/2011 | US20110177082 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 07/21/2011 | US20110177079 Cancer-testis antigens |
| 07/21/2011 | US20110177075 Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy |
| 07/21/2011 | US20110177074 Compositions and methods for inhibiting pdgfrbeta and vegf-a |
| 07/21/2011 | US20110177070 TGF-Beta Antagonist Multi-Target Binding Proteins |
| 07/21/2011 | US20110177068 Pharmaceutical preparation comprising an antibody against the egf receptor |
| 07/21/2011 | US20110177067 Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) |
| 07/21/2011 | US20110177066 Prevention and treatment of amyloidogenic diseases |
| 07/21/2011 | US20110177064 Compositions and Methods for Treatment of Ovarian Cancer |
| 07/21/2011 | US20110177063 Methods for treating colorectal cancer |
| 07/21/2011 | US20110177062 Methods for treating breast cancer |
| 07/21/2011 | US20110177060 Iap bir domain binding compounds |
| 07/21/2011 | US20110177058 Methods and compositions for modulating hgf/met |
| 07/21/2011 | US20110177056 Non-cytotoxic fusion proteins comprising egf muteins |
| 07/21/2011 | US20110177055 Compounds and compositions as channel activating protease inhibitors |
| 07/21/2011 | US20110177045 Use of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders |
| 07/21/2011 | US20110177036 Whole blood cultures comprising stimulated immune cells, and use thereof as medicaments |
| 07/21/2011 | US20110177032 Use on oncolytic herpes viruses for killing cancer stem cells |
| 07/21/2011 | US20110177027 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
| 07/21/2011 | US20110177011 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds |
| 07/21/2011 | US20110177009 Drug carrier providing mri contrast enhancement |
| 07/21/2011 | US20110177007 Dithienopyrrole Dyes for Imaging and Therapy |
| 07/21/2011 | US20110177006 Dithienofuran Dyes for Imaging and Therapy |
| 07/21/2011 | US20110177005 Stable nanoemulsions for ultrasound-mediated drug delivery and imaging |
| 07/21/2011 | US20110176998 Imaging and therapy of virus-associated tumors |
| 07/21/2011 | US20110176997 Method to make porous materials and their applications |
| 07/21/2011 | US20110176996 Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof |
| 07/21/2011 | US20110176994 Buoyant Polymer Particles for Delivery of Therapeutic Agents to the Central Nervous System |
| 07/21/2011 | US20110176993 Vegf polymorphisms and anti-angiogenesis therapy |
| 07/21/2011 | DE102010005131A1 Elements comprise on one side, one or more molecules with which they can dock to cancer cells and on other side, one or more molecules as element to be eliminated (e.g. pathogen) with which they are identified by the immune system |
| 07/21/2011 | CA2799474A1 Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring |
| 07/21/2011 | CA2787260A1 Methods and compositions for nanoparticle-mediated cancer cell-targeted delivery |
| 07/21/2011 | CA2787225A1 Methods for predicting response of triple-negative breast cancer to therapy |
| 07/21/2011 | CA2786957A1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 |
| 07/21/2011 | CA2786800A1 Thiazole and oxazole kinase inhibitors |
| 07/21/2011 | CA2786745A1 Wnt-binding agents and uses thereof |
| 07/21/2011 | CA2786660A1 Liver targeting molecules |
| 07/21/2011 | CA2786465A1 Certain chemical entities, compositions, and methods |
| 07/21/2011 | CA2785970A1 Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability |
| 07/20/2011 | EP2345974A1 Magnetically guidable compound |
| 07/20/2011 | EP2345720A2 In vivo production of small interfering RNAs that mediate gene silencing |
| 07/20/2011 | EP2345650A1 Amorphous (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole as anti-ulcer agent |
| 07/20/2011 | EP2345637A2 3, 10, and 12a substituted tetracycline compounds |
| 07/20/2011 | EP2345415A1 Therapeutic/prophylactic agent for prostate cancer |
| 07/20/2011 | EP2345409A1 Therapeutic agent for adult t-cell leukemia |
| 07/20/2011 | EP2345405A1 Substance for restoring normal co-expression and interaction between LOX and NRAGE proteins |
| 07/20/2011 | EP2344666A2 Ubiquitin specific proteases responsible for mcl-1 stability and uses thereof |
| 07/20/2011 | EP2344539A1 Treatment of pediatric acute lymphoblastic leukemia |
| 07/20/2011 | EP2344528A1 Pharmaceutical being used for treating cancer and fibrosis disease and the composition and uses thereof |
| 07/20/2011 | EP2344504A1 Pyrrolotriazine kinase inhibitors |
| 07/20/2011 | EP2344494A1 Aminotriazolopyridines and their use as kinase inhibitors |
| 07/20/2011 | EP2344493A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 07/20/2011 | EP2344492A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 07/20/2011 | EP2344490A2 4-morpholino-pyrido[3,2-d]pyrimidines active on pi3k |
| 07/20/2011 | EP2344486A2 Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof |
| 07/20/2011 | EP2344484A1 S1p receptors modulators and their use thereof |
| 07/20/2011 | EP2344480A1 Fused heteroaryl diamide compounds useful as mmp-13 inhibitors |
| 07/20/2011 | EP2344476A2 Tricyclic carbamate jak inhibitors |
| 07/20/2011 | EP2344474A1 Picolinamide derivatives as kinase inhibitors |
| 07/20/2011 | EP2344473A1 Heterocyclic pim-kinase inhibitors |
| 07/20/2011 | EP2344465A1 Crystalline forms of (r) -5- [3-chloro-4-( 2, 3-dihydroxy-propoxy)-benz [z]ylidene]-2- [z]-propylimino) -3-0-tolyl-thiazolidin-4-one |
| 07/20/2011 | EP2344463A2 1,2 -thiazol yl derivatives as cannabinoid receptor ligands |
| 07/20/2011 | EP2344462A1 Pyrimide derivatives and their pharmaceutical use |
| 07/20/2011 | EP2344460A1 Novel imidazolidine compounds as androgen receptor modulators |
| 07/20/2011 | EP2344453A2 Activators of human pyruvate kinase |
| 07/20/2011 | EP2344446A1 S1p receptors modulators |
| 07/20/2011 | EP2344441A2 14-hydroxy-docosahexaenoic acid compounds |
| 07/20/2011 | EP2344253A1 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes |
| 07/20/2011 | EP2344204A2 Telomerase inhibitors and methods of use thereof |
| 07/20/2011 | EP2344192A2 Method of making a vaccine |
| 07/20/2011 | EP2344184A2 Methods for inducing a sustained immune response againts a b-cell idiotype using autologous anti-idiotypic vaccines |
| 07/20/2011 | EP2344165A2 Pharmaceutical compositions comprising boronic acid compounds |
| 07/20/2011 | EP2344164A1 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| 07/20/2011 | EP2344161A1 Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| 07/20/2011 | EP2344156A1 Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent |
| 07/20/2011 | EP2344150A2 Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor |
| 07/20/2011 | EP2344148A2 Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| 07/20/2011 | EP2344147A2 Nutritional support of the immune system during anti-cancer treatment |
| 07/20/2011 | EP2168581A9 Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 07/20/2011 | EP2111228B1 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis |
| 07/20/2011 | EP2094699B1 New imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular cdc7 |
| 07/20/2011 | EP1545613B1 Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 07/20/2011 | EP1482920B2 Compositions containing n-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
| 07/20/2011 | EP1458748B1 Apoptotically active peptides |
| 07/20/2011 | EP1377578B1 Beta-carboline derivatives and its pharmaceutical use against depression and anxiety |
| 07/20/2011 | EP1361884B1 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus |
| 07/20/2011 | EP1214097B3 Nucleic acids encoding polyepitope polypeptides |
| 07/20/2011 | EP1157043B1 Anti-gpr-9-6 and anti-teck antibodies and methods of identifying modulators of gpr-9-6 and teck functions |
| 07/20/2011 | EP1053256B1 Antibodies to death receptor 4 (dr4) and uses thereof |
| 07/20/2011 | CN1993469B Recombinant alpha-fetoprotein, method and means for preparation thereof, compositions on the base thereof and use thereof |
| 07/20/2011 | CN1939311B Ginseng sapogenin aglycone derivative biological preparation and its usage |
| 07/20/2011 | CN102131926A Transfection agent |
| 07/20/2011 | CN102131828A Antibodies to human programmed death receptor pd-1 |
| 07/20/2011 | CN102131814A New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, process for preparing them, and application thereof in therapy as anticancer agents |
| 07/20/2011 | CN102131809A Tri-cyclic pyrazolopyridine kinase inhibitors |